会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • Self-precipitating pharmaceutical formulations for the moified release of an active principle
    • 用于释放活性成分的自沉淀药物制剂
    • US20090011028A1
    • 2009-01-08
    • US12149541
    • 2008-05-05
    • Frederic ChecotCecile Bonnet-GonnetYou-Ping ChanOlivier BreyneRemi Meyrueix
    • Frederic ChecotCecile Bonnet-GonnetYou-Ping ChanOlivier BreyneRemi Meyrueix
    • A61K47/42A61K9/10A61K38/20
    • A61K9/0019A61K9/10A61K9/1641A61K38/02A61K47/645A61K48/00
    • The present invention relates to novel pharmaceutical formulations for the release of an active principle (AP) over a sustained period of time of several days, or even several weeks.The invention relates, in a first aspect, to a liquid formulation comprising at least one active principle (AP) and an aqueous suspension based on colloïdal particles of a polymer (PO), wherein said formulation satisfies the following four conditions:(a) the polymer (PO) is a polyamino acid comprising glutamic residues, wherein some glutamic residues each carry a pendant cationic group (CG), said cationic groups being identical or different from one another, and other glutamic residues each carry a pendent hydrophobic group (GH), said hydrophobic groups (GH) being identical or different from one another, (b) the pHf value of the pH of said formulation is between 3.0 and 6.5; (c) at the pHf value, the polymer (PO) forms a colloïdal solution which associates spontaneously and noncovalently with the active principle (AP); (d) 1 ml of said formulation precipitates during mixing with a volume of 1 ml of a test buffer solution Tp. The invention also relates to a process for the preparation of such formulations and to a process for the preparation of medicaments including such formulations.
    • 本发明涉及用于在持续的几天甚至几周的时间内释放活性成分(AP)的新型药物制剂。 本发明在第一方面涉及包含至少一种活性成分(AP)和基于聚合物(PO)的胶体颗粒的水性悬浮液的液体制剂,其中所述制剂满足以下四个条件:(a) 聚合物(PO)是包含谷氨酸残基的聚氨基酸,其中一些谷氨酸残基各自携带阳离子基团(CG),所述阳离子基团彼此相同或不同,并且其它谷氨酸残基各自携带悬垂疏水基团(GH) ,所述疏水基团(GH)彼此相同或不同,(b)所述制剂的pH值的pHf值为3.0至6.5; (c)在pHf值下,聚合物(PO)形成一种自发和非共价结合活性成分(AP)的胶体溶液; (d)1ml所述制剂在与1ml测试缓冲溶液Tp的体积混合期间沉淀。 本发明还涉及一种制备这些制剂的方法以及制备包括这些制剂的药物的方法。
    • 2. 发明授权
    • Polyglutamic acids functionalized by cationic groups and hydrophobic groups and applications thereof, in particular therapeutic applications thereof
    • 由阳离子基团和疏水基团官能化的聚谷氨酸及其应用,特别是其治疗应用
    • US08716217B2
    • 2014-05-06
    • US12149542
    • 2008-05-05
    • You-Ping ChanCecile Bonnet-GonnetOlivier Breyne
    • You-Ping ChanCecile Bonnet-GonnetOlivier Breyne
    • A61K38/00A61K47/30A61K48/00C08G63/00
    • C08G69/10A61K9/10A61K47/34A61K47/645C08G69/48
    • The present invention relates to novel biodegradable materials based on modified polyamino acids that are useful in particular in the vectorization of active principle(s) (APs). The invention is also directed to novel pharmaceutical, cosmetic, health-food or plant-protection compositions based on these polyamino acids.The aim of the invention is to provide a novel polymeric starting material which can be used for AP vectorization and which satisfy all the requirements: biocompatibility, biodegradability, ability to easily associate with or dissolve numerous active principles and to release these active principles in vivo. This goal is achieved by the present invention, which relates to novel polyglutamates modified by cationic groups, which, if they can be deprotonated, exhibit a pKa equal to or greater than 7, and by hydrophobic groups comprising from 8 to 30 carbon atoms.These polyglutamates modified by cationic groups are easily and economically converted into particles for the vectorization of active principles, these particles being themselves capable of forming stable aqueous colloidal suspensions. These modified polyglutamates exhibit the advantage of being less viscous than other analogous polymers while retaining an ability to associate proteins, such as insulin. Some are soluble in water at acidic pH and become insoluble at physiological pH (7.4) and should thus, during subcutaneous injection, precipitate on the site of injection.
    • 本发明涉及基于改性聚氨基酸的新型可生物降解材料,其特别用于活性成分(AP)的向量化。 本发明还涉及基于这些聚氨基酸的新型药物,化妆品,保健食品或植物保护组合物。 本发明的目的是提供一种新颖的聚合起始材料,其可用于AP向量化,并且其满足所有要求:生物相容性,生物降解性,容易地与许多活性成分缔合或溶解的能力,并在体内释放这些活性成分。 该目的通过本发明来实现,本发明涉及由阳离子基团修饰的新的聚谷氨酸,如果它们可以去质子化,表现出等于或大于7的pKa,以及含有8至30个碳原子的疏水基团。 通过阳离子基团改性的这些聚谷氨酸可容易且经济地转化成用于活性成分载体化的颗粒,这些颗粒本身能够形成稳定的水性胶态悬浮液。 这些改性的聚谷氨酸显示出比其它类似聚合物粘稠度较低的优点,同时保留了使蛋白质如胰岛素相关联的能力。 一些在酸性pH下溶于水,在生理pH(7.4)下变得不溶,因此皮下注射时,在注射部位沉淀。
    • 4. 发明申请
    • Modified-release particles of polyelectrolytes and pharmaceutical formulations thereof
    • 聚电解质的改性释放颗粒及其药物制剂
    • US20090011039A1
    • 2009-01-08
    • US12149552
    • 2008-05-05
    • Cecile Bonnet-GonnetFrederic ChecotYou-Ping ChanOlivier Breyne
    • Cecile Bonnet-GonnetFrederic ChecotYou-Ping ChanOlivier Breyne
    • A61K47/30A61K9/14
    • A61K9/5146A61K9/1641
    • The present invention relates to novel particles comprising polyelectrolyte polymers which are transporters of active principle (AP), in particular protein and peptide active principle, and to novel modified-release pharmaceutical formulations comprising said AP microparticles.These novel particles loaded with AP release the AP over a prolonged period of time of several days, or even several weeks.The invention relates, in a first aspect, to particles comprising: a) a first polyelectrolyte polymer (PE1) in a charged state, carrying side hydrophobic groups (GH), wherein said first polyelectrolyte polymer (PE1) can spontaneously form, in water, a colloidal solution of particles at least one pHm value of the pH of between 3 and 8; b) a second polyelectrolyte polymer (PE2) of opposite polarity to the first polyelectrolyte polymer (PE1), wherein said second polyelectrolyte polymer (PE2) forms, in water, a solution or a colloidal solution at said pHm value of the pH; and c) at least one active principle (AP) associated noncovalently with the particles of the colloidal solution of the first polyelectrolyte polymer (PE1); wherein said particles are obtained by mixing, at a pH equal to pHm, the first polyelectrolyte polymer (PE1), in the form of a colloidal solution of particles associated with the active principle (AP), with the second polyelectrolyte polymer (PE2), in the form of a solution or colloidal solution. The invention also relates to the process for the preparation of these particles, to a pharmaceutical formulation comprising such particles and to a process for the preparation of medicaments.
    • 本发明涉及包含聚电解质聚合物的新型颗粒,其为活性成分(AP)的转运体,特别是蛋白质和肽活性成分,以及包含所述AP微粒的新型改性释放药物制剂。 装载AP的这些新型颗粒在几天甚至几周的较长时间内释放AP。 本发明在第一方面涉及包含以下的颗粒:a)带电状态的第一聚电解质聚合物(PE1),其携带侧疏水基团(GH),其中所述第一聚电解质聚合物(PE1)可在水中自发形成, 颗粒的胶体溶液,其pH值在3至8之间的至少一个pHm值; b)与第一聚电解质聚合物(PE1)相反极性的第二聚电解质聚合物(PE2),其中所述第二聚电解质聚合物(PE2)在水中以所述pHm的pH值在水中形成溶液或胶体溶液; 和c)与第一聚电解质聚合物(PE1)的胶体溶液的颗粒非共价结合的至少一种活性成分(AP); 其中所述颗粒是通过在等于pHm的pH下,以与活性成分(AP)相关的颗粒的胶态溶液与第二聚电解质聚合物(PE2)的形式混合第一聚电解质聚合物(PE1)而获得的, 以溶液或胶体溶液的形式存在。 本发明还涉及制备这些颗粒的方法,包括这种颗粒的药物制剂和制备药物的方法。
    • 5. 发明授权
    • Modified-release particles of polyelectrolytes and pharmaceutical formulations thereof
    • US08481019B2
    • 2013-07-09
    • US12149552
    • 2008-05-05
    • Cecile Bonnet-GonnetFrédéric ChecotYou-Ping ChanOlivier Breyne
    • Cecile Bonnet-GonnetFrédéric ChecotYou-Ping ChanOlivier Breyne
    • A61K31/74
    • A61K9/5146A61K9/1641
    • The present invention relates to novel particles comprising polyelectrolyte polymers which are transporters of active principle (AP), in particular protein and peptide active principle, and to novel modified-release pharmaceutical formulations comprising said AP microparticles.These novel particles loaded with AP release the AP over a prolonged period of time of several days, or even several weeks.The invention relates, in a first aspect, to particles comprising: a) a first polyelectrolyte polymer (PE1) in a charged state, carrying side hydrophobic groups (GH), wherein said first polyelectrolyte polymer (PE1) can spontaneously form, in water, a colloidal solution of particles at least one pHm value of the pH of between 3 and 8; b) a second polyelectrolyte polymer (PE2) of opposite polarity to the first polyelectrolyte polymer (PE1), wherein said second polyelectrolyte polymer (PE2) forms, in water, a solution or a colloidal solution at said pHm value of the pH; and c) at least one active principle (AP) associated noncovalently with the particles of the colloidal solution of the first polyelectrolyte polymer (PE1); wherein said particles are obtained by mixing, at a pH equal to pHm, the first polyelectrolyte polymer (PE1), in the form of a colloidal solution of particles associated with the active principle (AP), with the second polyelectrolyte polymer (PE2), in the form of a solution or colloidal solution. The invention also relates to the process for the preparation of these particles, to a pharmaceutical formulation comprising such particles and to a process for the preparation of medicaments.
    • 6. 发明申请
    • Polyglutamic acids functionalized by cationic groups and hydrophobic groups and applications thereof, in particular therapeutic applications thereof
    • 由阳离子基团和疏水基团官能化的聚谷氨酸及其应用,特别是其治疗应用
    • US20090012028A1
    • 2009-01-08
    • US12149542
    • 2008-05-05
    • You-Ping ChanCecile Bonnet-GonnetOlivier Breyne
    • You-Ping ChanCecile Bonnet-GonnetOlivier Breyne
    • A61K47/36A61K31/711A61K31/7105C08G63/685
    • C08G69/10A61K9/10A61K47/34A61K47/645C08G69/48
    • The present invention relates to novel biodegradable materials based on modified polyamino acids that are useful in particular in the vectorization of active principle(s) (APs). The invention is also directed to novel pharmaceutical, cosmetic, health-food or plant-protection compositions based on these polyamino acids.The aim of the invention is to provide a novel polymeric starting material which can be used for AP vectorization and which satisfy all the requirements: biocompatibility, biodegradability, ability to easily associate with or dissolve numerous active principles and to release these active principles in vivo. This goal is achieved by the present invention, which relates to novel polyglutamates modified by cationic groups, which, if they can be deprotonated, exhibit a pKa equal to or greater than 7, and by hydrophobic groups comprising from 8 to 30 carbon atoms.These polyglutamates modified by cationic groups are easily and economically converted into particles for the vectorization of active principles, these particles being themselves capable of forming stable aqueous colloidal suspensions. These modified polyglutamates exhibit the advantage of being less viscous than other analogous polymers while retaining an ability to associate proteins, such as insulin. Some are soluble in water at acidic pH and become insoluble at physiological pH (7.4) and should thus, during subcutaneous injection, precipitate on the site of injection.
    • 本发明涉及基于改性聚氨基酸的新型可生物降解材料,其特别用于活性成分(AP)的向量化。 本发明还涉及基于这些聚氨基酸的新型药物,化妆品,保健食品或植物保护组合物。 本发明的目的是提供一种新颖的聚合起始材料,其可用于AP向量化,并且其满足所有要求:生物相容性,生物降解性,容易地与许多活性成分缔合或溶解的能力,并在体内释放这些活性成分。 该目的通过本发明来实现,本发明涉及由阳离子基团修饰的新的聚谷氨酸,如果它们可以去质子化,表现出等于或大于7的pKa,以及含有8至30个碳原子的疏水基团。 通过阳离子基团改性的这些聚谷氨酸可容易且经济地转化成用于活性成分载体化的颗粒,这些颗粒本身能够形成稳定的水性胶态悬浮液。 这些改性的聚谷氨酸显示出比其它类似聚合物粘稠度较低的优点,同时保留了使蛋白质如胰岛素相关联的能力。 一些在酸性pH下溶于水,在生理pH(7.4)下变得不溶,因此皮下注射时,在注射部位沉淀。
    • 7. 发明申请
    • Pharmaceutical formulations for the prolonged release of active principle(s), and their applications, especially therapeutic applications
    • 用于延长释放活性成分的药物制剂及其应用,特别是治疗应用
    • US20080026070A1
    • 2008-01-31
    • US11808456
    • 2007-06-11
    • Cecile Bonnet-Gonnet
    • Cecile Bonnet-Gonnet
    • A61K9/14A61K31/70A61K31/715A61K38/02A61K38/21A61P3/00A61P35/00A61P25/00A61K38/27A61K38/28A61K47/30
    • A61K9/10A61K9/1635A61K31/70A61K31/715A61K38/212A61K38/27A61K38/28A61K47/34
    • The present invention relates to novel pharmaceutical formulations based on aqueous colloidal suspensions for the prolonged release of one or more active principles—AP—particularly protein and peptide active principles, and to the applications, especially therapeutic applications, of these formulations. This formulation comprises an aqueous colloidal suspension of low viscosity based on micrometric particles of a water-soluble, biodegradable, amphiphilic polymer PO carrying hydrophobic groups (GH)— alpha-tocopherol—and ionizable hydrophilic groups (GI)—Glu—that are at least partially ionized, said particles being capable of associating spontaneously and non-covalently with an AP, at pH=7.0, under isotonic conditions, and having a size of between 0.5 and 100 μm. This suspension contains multivalent ions (Mg++) of opposite polarity to that of the group GI of the PO, the ratio r, defined by the formula r = n × [ IM ] [ GI ] , where n is the valency of said multivalent ions, [IM] is the molar concentration of multivalent ions, [GI] is the molar concentration of ionizable groups GI, being between 0.3 and 10.
    • 本发明涉及基于水性胶体悬浮液的新型药物制剂,用于延长释放这些制剂的一种或多种活性成分,特别是蛋白质和肽活性成分,以及应用,特别是治疗应用。 该制剂包含基于水溶性,可生物降解的两亲性聚合物PO的微量颗粒的低粘度的水性胶体悬浮液,其携带疏水基团(GH)-α-生育酚和可离子化亲水基团(GI)-Glu-至少是至少 部分电离,所述颗粒能够在等渗条件下在pH = 7.0下自发和非共价地与AP缔合,并且具有0.5至100μm的大小。 该悬浮液含有与PO的组GI相反极性的多价离子(Mg ++),由式 r = n > MI> GI ] 其中n是所述多价离子的化合价,[IM]是多价离子的摩尔浓度,[GI]是可离子化基团GI的摩尔浓度,在0.3和10之间。